Wilsons Equity Research Report Issued with Buy Rating
Sydney, June 8, 2017 AEST (ABN Newswire) - Wilsons maintain a BUY rating and $1.66 price target. Anatara's (
ASX:ANR) recent stock underperformance has simply reflected a slow quarter for news in the lead-up to a significant inflection point in the 2H. Behind the scenes, Zoetis' evaluation work with Detach is ongoing and we are comfortable that Anatara has done the work in supporting that. If Zoetis does exercise its option to license Detach, then we see potential valuation upside to $2.50 per share.
Zoetis is already calling out a negative impact on their medicated feed additive sales just three months into the Veterinary Feed Directive rules coming into force, which switched key swine and cattle products from over-the-counter to prescription only. Zoetis has led the industry on the "antibiotic stewardship" issue and we think it has genuine intentions towards making Detach available to producers.
Wilsons Equity Research
Issued by Wilsons Advisory and Stockbroking Limited ABN 68 010 529 665 - Australian Financial Services Licence No 238375, a participant of ASX Group and should be read in conjunction with the disclosures and disclaimer in this report. Important disclosures regarding companies that are subject of this report and an explanation of recommendations can be found at the end of this document.
To view the Research Report, please visit:
http://abnnewswire.net/lnk/3696T3S9
About Anatara Lifesciences Limited
Anatara Lifesciences Limited (ASX:ANR) is developing and commercialising innovative, evidence-based products for gastrointestinal health where there is significant unmet need. Anatara is a life sciences company with expertise in developing productsfor human and animal health. Anatara is focused on building a pipeline of human gastrointestinal health products. Underlying this product development program is our commitment to delivering real outcomes for patients and strong value for our shareholders.
| ||
|
